Drug Type ASO |
Synonyms- |
Target |
Mechanism LRRK2 modulators(Leucine-rich repeat serine/threonine-protein kinase 2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Central Nervous System Diseases | Preclinical | DE | 01 Dec 2024 |